cyclophosphamide + docetaxel + doxorubicin + zoledronic acid

This is a combination regimen consisting of four drugs: - Cyclophosphamide, an alkylating agent that damages DNA and prevents cancer cell replication. - Docetaxel, a taxane that disrupts microtubule function, inhibiting cell division. - Doxorubicin, an anthracycline antibiotic that intercalates DNA and inhibits topoisomerase II, leading to DNA damage and apoptosis. - Zoledronic acid, a bisphosphonate that inhibits osteoclast-mediated bone resorption. The combination of cyclophosphamide, docetaxel, and doxorubicin (often referred to as TAC) is used as first-line chemotherapy for breast cancer—especially metastatic or high-risk early-stage disease—due to its high response rates[1][3][5]. Zoledronic acid is added in patients with bone metastases or at risk for skeletal-related events; it reduces the risk of fractures and other complications by strengthening bones[6][10]. The overall mechanism involves direct cytotoxicity against tumor cells (by the three chemotherapeutic agents) combined with protection against bone complications from malignancy (by zoledronic acid).

Other names

TAC plus zoledronic acid